Drugs, money and society (Part II)
- PMID: 20716232
- PMCID: PMC2949904
- DOI: 10.1111/j.1365-2125.2009.03569.x
Drugs, money and society (Part II)
Abstract
Pharmacoeconomics started as marketing but has developed into a valuable tool in the fuller assessment of drug therapies. Its principles are now widely accepted, and many countries have government-funded agencies with responsibility for its application, most notably the National Institute for Health and Clinical Excellence in England. Many clinical pharmacologists are active in this area, and the discipline itself is part of the clinical pharmacology trainees' curriculum. Further developments will include value-based pricing and its use in cost sharing arrangements between health service and manufacturers.
Similar articles
-
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?Br J Clin Pharmacol. 2010 Sep;70(3):360-6. doi: 10.1111/j.1365-2125.2010.03740.x. Br J Clin Pharmacol. 2010. PMID: 20716236 Free PMC article.
-
Pharmacoeconomics: NICE's approach to decision-making.Br J Clin Pharmacol. 2010 Sep;70(3):346-9. doi: 10.1111/j.1365-2125.2009.03589.x. Br J Clin Pharmacol. 2010. PMID: 20716233 Free PMC article. No abstract available.
-
From NCE to NICE: the role of pharmacoeconomics.Br J Clin Pharmacol. 2010 Sep;70(3):317-9. doi: 10.1111/j.1365-2125.2010.03708.x. Br J Clin Pharmacol. 2010. PMID: 20716229 Free PMC article. No abstract available.
-
Pharmacoeconomics: basic concepts and terminology.Br J Clin Pharmacol. 1997 Apr;43(4):343-8. doi: 10.1046/j.1365-2125.1997.00574.x. Br J Clin Pharmacol. 1997. PMID: 9146844 Free PMC article. Review. No abstract available.
-
[Application of pharmacoeconomics in clinical management].Farm Hosp. 2011 May;35 Suppl 2:18-24. doi: 10.1016/S1130-6343(11)70018-6. Farm Hosp. 2011. PMID: 22445505 Review. Spanish.
Cited by
-
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?Br J Clin Pharmacol. 2010 Sep;70(3):360-6. doi: 10.1111/j.1365-2125.2010.03740.x. Br J Clin Pharmacol. 2010. PMID: 20716236 Free PMC article.
-
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163. eCollection 2014 Sep 26. World J Methodol. 2014. PMID: 25332915 Free PMC article. Review.
References
-
- Hiatt HH. Protecting the medical commons: who is responsible? N Engl J Med. 1975;293:235–41. - PubMed
-
- Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services. London: Royal Society of Medicine; 1999.
-
- Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, Schwartz JS. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med. 1991;324:1362–5. - PubMed
-
- Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med. 1994;331:669–70. - PubMed
-
- Sacristán JA, Bolaños E, Hernández JM, Soto J, Galende I. Publication bias in health economic studies. Pharmacoeconomics. 1997;11:289–92. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources